A Phase I, Single-Center, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
Latest Information Update: 12 Nov 2024
At a glance
- Drugs Tezampanel (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions
- Sponsors Proniras Corporation
Most Recent Events
- 06 Nov 2024 Status changed from not yet recruiting to recruiting.
- 07 Aug 2024 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health:NCT06538558).
- 07 Aug 2024 Status changed from planning to not yet recruiting.